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Antagonists of protein–protein interactions
Andrea G Cochran
Protein–protein interactions are often attractive, but not
straightforward, targets for disease therapy. Two strategies for
identifying inhibitors of these interactions, peptide phage
display and high-throughput screening, have recently shown
new promise. 
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Introduction
The work of a living cell is performed largely by proteins,
sometimes alone but often in concert with partners.
Much of this activity is mediated by enzymes such as
kinases, proteases or glycosylases. However, many regu-
lated processes are initiated or inhibited through specific
protein–protein complex formation. Cytokine signaling
and transcription are examples. With the availability of
complete genome sequences, it has been estimated that
the number of interacting protein pairs in Escherichia coli
may be 6800 or more, and in Saccharomyces cerevisiae may
exceed 45,000 [1]. No doubt in humans the number will
be much higher, and many of these interactions will ulti-
mately become pharmaceutical targets. Protein–protein
interactions are generally quite specific, and much can be
learned about their function through genetic and bio-
chemical means. Despite the availability of such detailed
information, these interactions are considered difficult
small-molecule targets. This review will outline some of
the difficulties and summarize the results that have
emerged so far in the field, without attempting to be
exhaustive. In particular, I will not discuss G-protein-
coupled (7 TM) receptors or small docking modules,
such as WW, Src homology (SH3), or PDZ domains, that
bind short continuous peptide sequences (see [2–4] for
some recent advances). Instead, I will discuss systems in
which both binding partners are fairly large soluble pro-
teins (or soluble, independently folded domains of a
protein), with binding contacts spread over a surface.
Often this type of binding surface includes discontinuous
parts of the protein sequence, sometimes from more than
one protein domain. The complex of human growth
hormone and its receptor is a good example of this type
(Figure 1) [5,6].
What is a small molecule, and why are
protein–protein targets so hard?
When discussing small molecules as potential pharmaceu-
tical agents, the ultimate goal is in vivo efficacy, and devel-
oping such molecules is far from trivial. Ideally, one wants
not only high potency against the target protein, but also
low toxicity, few side effects and good bioavailability,
preferably oral bioavailability. Some efforts have been
made to analyze databases of existing drugs (about 5000
compounds) in order to define those properties that make
a molecule ‘drug-like’ [3,7–10]. Very generally, molecular
weights less than about 500 are preferred, and molecules
that are either extremely hydrophobic or extremely
hydrophilic are not considered optimal. There are very
few reports of drug-like molecules disrupting protein–
protein interfaces.
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Historically, many efforts to discover low molecular
weight drug leads have focused on inhibiting enzymes
implicated in a particular disease state or on modifying
known, bioactive small molecules (neurotransmitters, for
example). There are some strategic advantages to these
choices. Most obvious of these is that knowing even one
substrate of an enzyme (or the structure of a small-mole-
cule ligand) provides information about what kinds of
other molecules might bind to the target protein, facilitat-
ing further design. This information is not obtained auto-
matically when protein-binding partners are identified.
Instead, mutagenesis experiments or structural studies
identify protein contact regions and pinpoint residues
most critical to binding. At this stage, many different
strategies are considered for transfer of epitopes to smaller
entities (peptide or nonpeptide). As yet, there is no
general solution to this transfer problem. Alternatively,
one may screen compound libraries directly for small-mol-
ecule inhibitors, or in the case of peptides, select ligands
using phage-display methods.
It is important to realize that small-molecule discovery
against protein–protein targets is genuinely difficult, but
not for one of the reasons commonly assumed. It is often
stated that a small molecule would require the affinity of
the protein (frequently subnanomolar) to successfully
compete for binding to its site [11,12]. This assumption is
false. For the simplest case of inhibitor I competing with
protein P2 for binding to protein P1, the equilibria are
shown in Figure 2a. The fraction of P1 bound to P2 can be
expressed in an equation analogous to that describing
competitive enzyme inhibition (Figure 2a). Plotting this
fraction as a function of added inhibitor yields a typical
displacement curve, as shown in Figure 2b for several con-
centrations of the protein competitor P2. How well the
ligands compete for P1 is determined not by their relative
binding constants but by the ratio of each ligand’s concen-
tration to its own binding constant. This is true for all
values of KP and KI (Figure 2). In other words, even a
protein with a picomolar binding constant will be unable
to compete with a weakly binding small molecule if the
concentration of the protein is very low and the small-mol-
ecule concentration is relatively high. Of course, the
limited solubility or bioavailability of many small mole-
cules and their potential toxicity are often practical
reasons to prefer higher affinity drug leads.
The sensitivity of protein–protein interactions in vivo will
probably vary depending on both the levels of the proteins
present and how they are distributed in the organism, and
it may be critical to target the correct protein of the pair for
maximal effect. Intriguingly, analysis of signaling cascades
has indicated that the net output of a network may be more
sensitive to small changes in effector concentration (or
perhaps percent inhibition) than an individual protein com-
ponent [13,14]. In other cases, a system may respond over a
very wide range of effector concentrations [15], requiring
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Figure 2
(a) Competition binding equilibrium. P1 and P2 are proteins that
associate as the complex P1•P2. I is an inhibitor that binds to P1. The
boxed equation relates the fraction of P1 in the complex to the
concentrations and dissociation constants of the competitors P2 and I.
(b) The fraction of P1 in the complex is plotted as a function of added
inhibitor (relative to its dissociation constant KI) for several
concentrations of P2.
Figure 1
Complex of human growth hormone (red) and its receptor (blue) [75].
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more complete titration by an inhibitor. The prospect for
success in targeting a protein–protein interaction depends,
therefore, on the biology of the system.
Finally, understanding molecular recognition of protein
surfaces is a challenging physical chemistry problem. The
crystal structures of protein–protein complexes have been
surveyed to identify any features common to the contact
surfaces [16–18]. A ‘typical’ interface buries ~1600 Å2 of
protein surface area (~170 atoms); this area is evenly
divided between the two components, consistent with the
approximate flatness of protein interfaces [18]. Contact
atoms include those from both sidechains and the main-
chain. The residue composition of interfaces is not greatly
different from that of protein surfaces, although aromatic
residues and arginine appear somewhat more frequently
[17,18]. Burial of a hydrophobic surface can drive complex
formation [19], but hydrogen bonds, salt bridges and water
molecules occur in many interfaces.
It is unlikely that every part of a protein surface is suited
to binding small molecules, and considerable effort has
been made to identify those ligand sites that may be
present. These efforts include computational searches for
surface pockets in protein crystal structures ([20] and ref-
erences therein), crystallization of proteins in multiple
organic solvents [21], and nuclear magnetic resonance
(NMR)-based methods for screening libraries of small
organic compounds [22–25]. These experimental methods
are capable of identifying very low affinity ligands
(Kd > 1 mM) and the location of the protein-binding site.
Fesik and coworkers [22] have used such a procedure,
which they call ‘SAR by NMR’, to discover molecules
that occupy adjacent pockets on a target protein. Two
low-affinity ligands then can be linked to yield a high-
affinity ligand (Kd < 100 nM) [22,23]. These methods
have most often succeeded when targeting enzymes or
proteins with known small-molecule-binding sites (e.g.
the FK506-binding protein, FKBP [22]); in principle,
however, they might be used to explore protein–protein
recognition surfaces.
Scaffold reduction and epitope transfer:
proteins to miniproteins
An attractive way to develop molecules that antagonize a
protein–protein interaction would be to reproduce the
essential features of one of the protein partners in a much
smaller form. The critical assumption is that only a subset
of protein residues make energetically significant contacts
in the complex; the remainder are either completely
expendable, or they are needed to stably structure those
residues in contact. This idea has been tested by combin-
ing structural information, mutagenesis data and phage
display to systematically minimize small proteins [26].
These efforts yielded peptides of about half the original
size that retained nearly all of the original binding affinity. 
An example of this approach is the reduction of the
59-residue Z-domain from Protein A [27]. Z-domain is a
three-helix bundle that binds to immunoglobulin G
(IgG1) with a dissociation constant of 10 nM (Figure 3).
Although one of the helices makes no direct contact in
the complex crystal structure, deletion of this helix abol-
ished binding. Selection for variants that were capable of
binding (using phage-display methods) identified
12 mutations (of the 33 remaining residues) that, when
combined, restored much of the original affinity for IgG
(Kd = 43 nM). These mutations increased the helicity
(i.e. the structural stability) of the miniprotein; some
improvements were also made in the IgG contact surface
[27]. The stability and affinity of the minimized protein
were further improved by adding a disulfide, resulting in
a highly structured molecule that faithfully presents the
essential features of the original domain [28].
A different design strategy has been used to transfer key
binding contacts from the T-cell surface glycoprotein CD4
onto a much smaller scorpion toxin scaffold [29]. The toxin
fold is exceptionally stable, with three disulfides in 31
residues, and is therefore very tolerant of substitutions.
Thus, CD4 residues could be introduced into spatially
appropriate positions in the toxin without disrupting its fold.
In a first step, 11 mutations were made, and four residues
were deleted from the termini. This toxin variant competed
with CD4 for binding to HIV-1 gp120 (IC50 = 40 µM). The
affinity of the initial variant was improved about 100-fold by
combining alanine substitutions that individually enhanced
binding of the miniprotein, and by repositioning some of
the putative binding contacts. Importantly, the single most
critical residue in CD4 (Phe43) is absolutely critical in the
toxin, suggesting that the miniprotein binds to gp120 in the
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Figure 3
Model of the complex of Protein A Z-domain (purple) and IgG Fc [27]. 
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same way as the larger protein does. The final 28-residue,
mini-CD4 binds to gp120 about 100-fold more weakly than
soluble CD4 [29]. 
A designed mimic of interleukin-4 (IL-4) illustrates again
the principle of protein minimization [30]. IL-4 is a four-
helix bundle cytokine. One face of the bundle displays
the major binding contacts for the receptor IL-4Rα; these
are primarily segregated within two of the four helices.
Based on superposition of the structures of IL-4 and the
GCN4 coiled coil (a two-helix structure), eight residues
from IL-4 were transferred onto the surface of GCN4.
The resulting mimic was found to bind weakly to IL-4Rα
(Kd =26 µM for the mimic versus 1.4 nM for IL-4) [30].
Thermal denaturation studies indicated that the GCN4
mimic was partially unfolded. Stability and affinity could
be improved (3–5-fold) by addition of a disulfide to cross-
link the dimeric coiled coil [30].
These three examples illustrate that, beginning with
some structural and mutagenesis data, it is possible to
evolve or design smaller proteins that reproduce the
binding properties of their larger parents. Although the
CD4 and IL-4 miniproteins do not have the full affinity of
the original proteins, the results are nonetheless intrigu-
ing because little optimization was required. It will be
interesting to see whether further improvements in
binding can be made, and to what extent miniproteins can
be further minimized.
Proteins to peptides (or to peptidomimetics)
Although proteins may be reduced substantially in size as
described above, the reduced proteins are still quite a bit
larger than typical small-molecule drugs. It would be
advantageous, when possible, to skip protein minimization
and go directly to a much smaller peptide or pep-
tidomimetic. In certain cases, this approach has proven
remarkably successful. Unfortunately, it is not always so
simple. Protein-binding epitopes are seldom concentrated
in a short linear sequence or even in a single secondary
structural element. Furthermore, short peptides are gener-
ally not structured as they might be when embedded
within a protein domain. These factors combine to limit
the information that may be transferred from a protein
into a related peptide. 
Despite these considerations, there have been many
reports of short peptides (10–20 amino acids taken from a
protein sequence) that compete with the protein for
target. In particular, disulfide constraint of protein surface
loops is commonly reported to yield peptide mimics. Such
reports should be viewed with caution, however. We have
tried (without success) to reproduce several published
claims of peptide mimicry of a large protein domain. It
requires some care to develop assays that work well with
peptides and small molecules, and it is important to
confirm any apparent ‘hits’ in secondary assays. As a
general rule with peptide inhibitors: if it looks too good to
be true, it probably is! 
With other inhibitors the mechanism of action may be dif-
ferent than expected. Peptidomimetics designed to
inhibit CD4 binding to HIV-1 gp120 [31] are an example
of this type. The original mimetic was based on the major
gp120-binding loop of CD4, and an IC50 of about 10 µM
was reported (on the basis of two cell-based assays). It was
later found, however, that a closely related mimetic did
not block gp120 binding to soluble CD4 in a competition
assay [32]. These molecules, therefore, cannot be consid-
ered true CD4 mimics.
By contrast, the interactions between integrins and cell
adhesion molecules (CAMs) can generally be blocked using
short peptides and by nonpeptide mimics (e.g. [33,34]).
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Figure 4
Subunit interface inhibitors. (a) Peptide (top)
and peptidomimetic (bottom) inhibitors of
herpes virus ribonucleotide reductase.
(b) Peptide (top) and natural product (bottom)
inhibitors of HIV protease. 
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Recently, it has been shown that an explicit connection can
be made between peptide structure–activity relationships
and protein mutagenesis data for vascular CAM (VCAM)
[35]. The crystal structure of a two-domain fragment of
VCAM was used to design eight-residue cyclic peptide
inhibitors intended to mimic the conformation of the
protein-binding loop. NMR structures of two peptides were
consistent with this design. Substitutions were made in the
cyclic peptide to match mutations that had been examined
previously in the protein. The changes in peptide IC50
values correlated with those observed for VCAM mutants,
suggesting that the peptides and VCAM bind in the same
way. Importantly, substitutions that increased inhibitory
potency in the peptide suggested new VCAM mutations
that improved its affinity for the integrin α4β1 [35]. This
study demonstrates that a binding epitope at a protein–
protein interface may be transferred, intact, to a peptide.
Dimerization inhibitors 
Enzyme dimerization interfaces appear to be another class
of interaction that can be disrupted using short peptides
derived from the protein [36]; this strategy has been most
frequently used to inhibit viral enzymes. It was discov-
ered in 1986 that the heterodimeric ribonucleotide reduc-
tase from herpes virus could be inhibited by short
peptides derived from the carboxyl terminus of the
smaller R2 subunit [37,38]. This carboxy-terminal
segment anchors the R2 subunit to the larger R1 subunit,
wedging between two helices on the surface of R1 [39].
Extensive analog synthesis led to the more hydrophobic
and much more potent (IC50 = 0.3 nM) peptidomimetic
BILD 1263 (Figure 4a) [40].
HIV protease is another enzyme that can be inhibited with
peptides derived from the subunit interface. In this case,
the enzyme is a homodimer, and the interface is a four-
stranded antiparallel β sheet, with strands from the amino-
and carboxy-terminal segments of each monomer [41,42].
The carboxyl termini provide the two central strands of the
sheet and are flanked by the amino termini. A tetrapeptide
derived from the carboxyl terminus was reported to inhibit
the enzyme with a Ki of 45 µM (Figure 4b); kinetic and
sedimentation analyses were consistent with inhibition by
dissociation of the protease dimer [43]. This report has
prompted many additional studies (reviewed in [36]). Of
particular interest is a recent report that simplified analogs
of the marine natural products didemnaketals A and B
inhibit HIV protease [44]. Seven of the eight possible
diastereomers of the didemnaketal sidechain fragment
(Figure 4b) gave Ki values ranging from 2 to 30 µM. Signif-
icantly, kinetic analysis supported the dissociative mecha-
nism [44]. It is tempting to speculate that the natural
product may be a mimic of the protease β strand. 
The inhibitory potency of simple linear peptides sug-
gests that the interfaces of dimeric enzymes may differ
structurally from other interfaces. It has been noted that
the surface buried in oligomer interfaces is unusually
hydrophobic [16,18]. Furthermore, for HIV protease, the
carboxy-terminal tetrapeptide contributes a large fraction
(~50%) of the total surface area buried in the dimer inter-
face [42]. For both of the examples described in the pre-
ceding paragraph, the inhibitory peptide is expected to
be significantly buried in the complex with target, rather
than binding to a more exposed surface. All of these
factors may combine to make subunit interfaces
amenable to small-peptide inhibition.
Peptides from phage display
About ten years ago, it was demonstrated that high-affinity
ligands could be selected from peptide libraries displayed
on bacteriophage [45–47]. Since then, quite a few success-
ful applications have been described, many directed
toward mimicking or antagonizing the function of a
protein ligand [48–50]. The real power of the technique is
that because the libraries can be very large (108 or more
individual members), no assumptions need be made ini-
tially about how to bias the library. Those sequences that
bind are amplified and can be identified easily by
sequencing their encoding DNA. Further optimization
often yields peptides of nanomolar affinity. Some targets
(e.g. antibodies) yield peptides homologous to known
ligands, whereas others yield entirely novel peptides
whose affinity might never have been predicted.
A remarkable example of this latter class is an erythropoi-
etin (EPO) agonist peptide that bears no resemblance to
the natural hormone yet binds to the hormone site as a
dimer, thus dimerizing and activating the receptor
(Figure 5) [51,52]. A subtle change in the 20-residue
peptide — substitution of 3,5-dibromotyrosine for a single
tyrosine residue — converts the agonist into an antagonist
[53]. Surprisingly, the crystal structure of the antagonist–
receptor complex revealed not only the same 2:2 stoi-
chiometry as the agonist–receptor complex, but also a shift
in orientation between receptor monomers that may
explain the shift to an antagonist [53].
Other antagonists of protein–protein interactions have
been discovered using phage libraries. These include
peptides blocking IL-1α binding to type I IL-1 receptor
[54], insulin-like growth factor 1 binding to its regulatory
binding protein IGFBP-1 [55], the angiogenesis factor
VEGF binding to its cell-surface receptor KDR [56,57],
IgG Fc binding to streptococcal Protein A [58], and HIV-1
gp120 binding to CD4 [59]. All of these peptides are
between 10 and 20 residues in length, still a bit large to
transform easily into small-molecule drug candidates.
They are also quite hydrophobic and tend to cover a large
surface on the target protein [52,57,58]. It will be a chal-
lenge to minimize these peptides without sacrificing their
potency. A combination of peptidomimetic design with
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diversity methods seems most likely to balance these
opposing forces.
Small molecules from screening
An exciting recent development is the identification of
small molecules capable of blocking (or in some cases,
promoting) cytokine receptor signaling. The first such
molecule was designed to mimic arginine and phenylala-
nine sidechains of interleukin-2 (IL-2) important for
binding to the α subunit of IL-2 receptor (Figure 6a)
[60]. The design was not successful, because the mimic
bound IL-2 itself; nevertheless, the molecule was a com-
petitive inhibitor of IL-2 binding to its receptor
(IC50 = 3 µM) and an important demonstration that such
inhibitors could be obtained. 
The next reported discovery was SB 247464 (Figure 6b),
an activator of the receptor for granulocyte-colony-stimu-
lating factor (G-CSF) [61]. This molecule was identified
in a high-throughput screen, and chimeric receptor
experiments indicate that it binds to the extracellular
portion of the receptor. Maximal activity is seen at
~1 µM. Interestingly, SB 247464 self-antagonizes at
about tenfold higher concentrations (see [15] for an
extensive discussion of this phenomenon). This observa-
tion and the twofold symmetry of the molecule suggest
that SB 247464 may bridge two receptor monomers; it
would be interesting to know how much of the structure
is required for the observed antagonism.
A third nonpeptide antagonist was discovered by screen-
ing a chemical library for inhibitors of human EPO
binding to the extracellular domain of the EPO receptor
[62]. A biphenyl indole derivative (Figure 6c) was found
to inhibit the interaction with an IC50 of 60 µM; a multiva-
lent synthetic intermediate acted as an EPO mimic.
The discovery of these antagonists is a real breakthrough,
and additional examples are likely to follow. For those
molecules identified through screening, it would be inter-
esting to know more about the numbers and types of com-
pounds screened and how many active molecules were
found. Nevertheless, considering the molecules together
(Figure 6), some similarities can be seen. All contain multi-
ple aromatic rings, connected by rigid linkers that might
be expected to prevent intramolecular hydrophobic col-
lapse. This is also the case for the insulin receptor activator
L-783,281 (Figure 6d). (This molecule binds to and acti-
vates the intracellular tyrosine kinase domain of the
insulin receptor (EC50 = 3–6 µM) rather than competing
for the insulin site [63]). The frequency of indoles is espe-
cially intriguing. It may be that such compounds are partic-
ularly well suited to binding protein surfaces. 
Comparing strategies: HIV fusion inhibitors
Viral entry mediated by HIV gp41 involves a protein–
protein interaction that has been the subject of much
recent interest [11,64]. Crystal structures of a stable
trimeric gp41 core domain (Figure 7a) [65–67] reveal a
central coiled coil (N36) buttressed by helical segments
from a more carboxy-terminal region of gp41 (C34). The
six-helix trimer is believed to correspond to one of the
species present during membrane fusion, probably during
the later stages of the process, and it is the interaction of
the carboxy-terminal helix with the surface of the coiled
coil that has become the target of numerous studies. 
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Figure 5
Complex of the EPO-binding protein and the
agonist peptide EMP-1. The complex contains
two peptide molecules (orange and red) and
two EPO-binding proteins (blue and light
green; figure reproduced from [48]). 
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It was discovered several years ago that the linear 36-mer
DP178 (derived from the gp41 sequence) could block viral
fusion at nanomolar concentrations [68]. DP178 partially
overlaps the carboxy-terminal helical segment seen in the
crystal structures (Figure 7b), and it seemed likely that
DP178 might bind in a helical conformation to an exposed
coiled coil in gp41. Evidence supporting this model came
from studies with truncated forms of DP178 that were cross-
linked to enforce an α-helical structure [69]. Shortening
DP178 to 27 residues abolished much of its potency,
whereas introducing one or two helical locks progressively
restored inhibitory potency of the 27-mer and increased
peptide helicity, suggesting a relationship between helical
structure and activity. Although the peptide with two locks
was nearly as potent as DP178, the peptide could not be
reduced much further in size [69]. A series of constrained 14-
mers covering the entire helical region seen in the structures
through the end of DP178 (48 residues total) failed to signif-
icantly inhibit viral infectivity, suggesting that an extended
surface interaction is required for effective inhibition. 
A further advance was made by Chan et al. [65,70] based on
analysis of the gp41 crystal structure. Near the carboxy-ter-
minal end of the central coiled-coil trimer, unusual interhe-
lical pockets are present (Figure 7c); sidechains from one
of the three exterior helices (Trp628, Trp631 and Ile635)
are accommodated by each of these pockets. Substitution
of any of these residues by alanine destabilized the struc-
ture of the soluble core domain (∆Tm = 11–29°C) and
reduced the inhibitory potency of the 34-residue peptide
[70]. Introducing a series of hydrophobic residues at the
position corresponding to Trp631 allowed the authors to
correlate log IC50 values (from two different assays) with
the melting temperature of the peptide complex. It
appears, therefore, that inhibition by the 34-residue
peptide requires not only that it adopt a helical conforma-
tion, but also that it form the complex with the central
coiled coil of gp41. These authors further propose that the
surface pocket of the central trimer may be a good target
for a therapeutic small molecule; however, neither short
linear peptides [70] nor helical constrained peptides [69]
corresponding to the pocket-binding part of the exterior
helix measurably inhibit viral infection. It seems, there-
fore, that the contacts between the pocket and its native
binding partner do not provide sufficient energy upon
which to build a small-molecule mimic.
However, two new efforts attempt to improve upon
nature. In the first of these, an 18-residue segment from
the gp41 outer helix (missing the residues that contact
the surface pocket of the central trimer discussed above)
was derivatized with non-natural building blocks added
in three steps of split-pool synthesis, creating a library of
61,275 potential inhibitors [71]. The three non-natural
elements were intended to fill the gp41 surface pocket in
the place of the isoleucine and the two tryptophan
sidechains. Positional deconvolution of the library
yielded 3-cyclopentylpropionyl as the favored terminal
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Figure 6
Small molecules that agonize or antagonize
cytokine signaling. (a) IL-2 antagonist.
(b) G-CSF receptor agonist (and antagonist,
see text for more details). (c) EPO antagonist.
(d) Insulin receptor agonist.
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group, followed by glutamic acid (coupled through the
γ-carboxylate), N-(2-carboxyethyl)-4-aminomethylben-
zoic acid, then the peptide. The hybrid peptide was
unable to bind to the central trimer when cleaved from
resin. However, the contribution of the non-natural ele-
ments to inhibitory potency could be determined by
extending the peptide portion from 18 to 30 residues.
The longer hybrid peptide inhibited cell fusion with an
IC50 of 0.3 µM, compared with 6.6 µM for the unmodi-
fied 30-mer, and 2.7 nM for a 38-mer peptide that
included the native isoleucine and tryptophan residues
[71]. Therefore, although the non-natural elements do
contribute some binding energy, the effect is modest,
equal to ~40% of the contribution of the native sequence.
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Figure 7
The gp41 core domain. (a) The amino-
terminal peptide from gp41 (N36) forms a
trimeric coiled coil, and the carboxy-terminal
peptide C34 binds to the outer surface of the
coiled coil [65]. (b) Sequences of C34 and
the fusion inhibitor DP178 [68]. (c) Surface
pocket in the N36 coiled-coil trimer
(reproduced with permission from [70]). 
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A quite different approach was reported by Eckert et al. [72]
who developed a family of D-peptide inhibitors using
phage-display methods. In order to target the surface pocket
of the central gp41 coiled coil directly, they designed a
chimeric trimer in which a very soluble and stable coiled
coil (based on GCN4) was fused, in heptad register, to 17
gp41 residues; these gp41 residues include all those needed
to define the pocket. Using this engineered target (synthe-
sized in D-form), 12 phage clones were ultimately selected.
Nine of these appear to bind specifically to the pocket
region of the target and define a family of 16-mer peptides
with a consensus sequence of GACX5EWXWLCAA. IC50
values for the nine peptides (now synthesized in D-form)
range from 3.6–130 µM. A crystal structure was determined
for one of the bound peptides [72]. The peptide does bind
to the pocket region of the target: the provocative observa-
tion is that the consensus tryptophan residues and leucine
of the peptide are presented on the surface of a helix, occu-
pying roughly the same positions as the tryptophan residues
and isoleucine of the native gp41 helix (although the
sidechain orientations do differ).
Considering all these studies together, one may conclude
that despite the observed surface pocket in the gp41
trimer the binding energy in the native complex is distrib-
uted rather evenly along the interhelical surface. Never-
theless, a binding selection can yield peptides that
resemble the native sequence in some key respects, but
have a larger interaction energy with the surface pocket.
Again, this highlights the power of phage display to
suggest solutions that would have been difficult to access
through structure-aided design. 
Future prospects
There have been many exciting developments that bring
small-molecule inhibitors of protein–protein interactions
closer to practical use. Much work remains, however, to
define which strategies will be most practical for discover-
ing such molecules, and which proteins will be the best
small-molecule targets. The very recent reports of the
first genome-scale protein–protein interaction maps (for
yeast) [73,74] suggest that biological chemists and struc-
tural biologists will have an abundance of interesting pos-
sibilities to explore.
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